Last updated: February 19, 2026
This report analyzes the Singaporean patent application SG10201809895Y, filed on November 2, 2018, by Amgen Inc. The application, titled "HUMAN ANTIBODIES THAT BIND TO PCSK9," claims novel antibodies and their use in treating hypercholesterolemia. The patent landscape indicates a competitive environment for PCSK9 inhibitors, with Amgen already holding established market positions.
What is the Subject Matter of SG10201809895Y?
The patent application SG10201809895Y pertains to human antibodies that inhibit Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). PCSK9 is a protein that plays a critical role in regulating low-density lipoprotein (LDL) cholesterol levels in the blood. By inhibiting PCSK9, these antibodies increase the number of LDL receptors on liver cells, thereby enhancing the clearance of LDL cholesterol from the bloodstream.
The disclosed antibodies are characterized by their specific binding epitopes on PCSK9 and their efficacy in reducing LDL cholesterol levels. The application details the sequence identification numbers (SEQ ID NOs) for the antibody variable regions, including heavy and light chains, as well as methods for producing and using these antibodies.
What are the Key Claims of SG10201809895Y?
The patent application SG10201809895Y outlines a series of claims focused on the novel antibodies, their compositions, and their therapeutic applications. The core claims center on the antibodies themselves and their specific structural and functional characteristics.
Claim 1 is directed to an isolated human antibody that binds to an epitope on PCSK9, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), with specific sequence identification numbers provided for these regions. This claim defines the antibody based on its amino acid sequence, establishing a precise structural definition.
Claim 2 is dependent on Claim 1 and further specifies that the VH region has a sequence identified by SEQ ID NO: 1 and the VL region has a sequence identified by SEQ ID NO: 2. This narrows the scope to a particular antibody defined by these specific sequences.
Claim 3 is also dependent on Claim 1, specifying different sequence identification numbers for the VH and VL regions, namely SEQ ID NO: 3 and SEQ ID NO: 4, respectively. This claim covers a second distinct antibody based on its amino acid sequence.
Claim 4 extends the scope to a composition comprising the antibody of any one of the preceding claims and a pharmaceutically acceptable carrier. This claim addresses the formulation of the antibody for therapeutic administration.
Claim 5 focuses on the therapeutic use of the antibody. It claims a method of treating a subject with hypercholesterolemia, comprising administering an effective amount of the antibody of any one of the preceding claims. Hypercholesterolemia is defined in the application as a condition characterized by elevated levels of cholesterol, including LDL cholesterol.
Claim 6 further specifies the therapeutic method by stating that the administration is effective in reducing the level of LDL cholesterol in the subject. This highlights the primary mechanism of action and therapeutic benefit.
Claim 7 specifies that the antibody may be a monoclonal antibody. This clarifies the type of antibody being claimed, which is typically produced from a single clone of cells.
Claim 8 covers a nucleic acid molecule encoding the antibody or an antigen-binding portion thereof. This claim encompasses the genetic material responsible for producing the therapeutic antibody.
Claim 9 relates to a host cell comprising the nucleic acid molecule of Claim 8. This addresses the production systems for the antibody.
Claim 10 defines a method of producing the antibody, which involves culturing the host cell of Claim 9 under conditions that promote expression of the antibody and recovering the antibody. This outlines the manufacturing process.
The claims collectively aim to protect the antibody itself, its formulations, its production, and its use in treating conditions associated with elevated cholesterol.
What is the Prior Art Landscape for PCSK9 Inhibitors?
The landscape for PCSK9 inhibitors is well-established, with significant prior art predating the filing of SG10201809895Y. Amgen itself is a dominant player in this field, having pioneered the development of fully human monoclonal antibodies targeting PCSK9.
The first approved PCSK9 inhibitor, evolocumab (marketed as Repatha), developed by Amgen, received FDA approval in August 2015. This was followed by alirocumab (Praluent), developed by Regeneron and Sanofi, which gained FDA approval in July 2015. These approvals signify a mature market with substantial intellectual property already in place.
Key patent families in this space include those covering:
- The PCSK9 protein itself: Early patents would have defined the target.
- Monoclonal antibodies targeting PCSK9: This includes patents claiming specific antibodies, their sequences, binding epitopes, and therapeutic uses. Amgen holds numerous patents related to evolocumab and its manufacturing. Regeneron and Sanofi also hold significant patent portfolios for alirocumab.
- Formulations and delivery devices: Patents related to the stable formulation of antibodies and convenient administration methods.
- Methods of treatment: Patents claiming the use of PCSK9 inhibitors for specific patient populations or therapeutic outcomes.
The existence of these established drugs and their associated patent protection means that any new entrant or innovation in the PCSK9 inhibitor space must demonstrate novelty and non-obviousness over this substantial body of prior art. SG10201809895Y appears to be an attempt by Amgen to further fortify its intellectual property position, potentially by claiming novel antibodies with improved characteristics or distinct binding profiles.
The competitive environment necessitates careful analysis of existing patents to avoid infringement and to identify opportunities for innovation. Companies operating in this area must navigate a complex web of intellectual property rights, including granted patents and pending applications.
How Does SG10201809895Y Relate to Amgen's Existing PCSK9 Portfolio?
Singapore patent application SG10201809895Y, if granted, would likely complement Amgen's existing PCSK9 inhibitor portfolio, which is primarily represented by evolocumab (Repatha). Evolocumab is a fully human monoclonal antibody that binds to PCSK9 and inhibits its interaction with the LDL receptor. The claimed antibodies in SG10201809895Y are also described as human antibodies that bind to PCSK9.
The specific sequences and binding epitopes disclosed in SG10201809895Y would determine its precise relationship to evolocumab. It is plausible that these claims represent:
- Next-generation antibodies: Antibodies with potentially improved potency, efficacy, half-life, or reduced immunogenicity compared to existing products like evolocumab. The specific SEQ ID NOs listed in the claims are crucial for determining if they correspond to novel antibody structures.
- Alternative antibodies: Antibodies that bind to a different epitope on PCSK9 than evolocumab, or antibodies with different pharmacokinetic or pharmacodynamic profiles. This could offer strategic advantages in terms of patent differentiation and therapeutic options.
- Back-up compounds: Development of alternative antibody candidates to ensure a continued pipeline and robust intellectual property protection even if existing patents face challenges or the market evolves.
Amgen's strategy typically involves securing broad patent protection around its key therapeutic assets. Filing applications like SG10201809895Y, even after successful market entry of a related product, is a common practice to extend intellectual property coverage and protect against potential competitors. Without direct comparison of the specific SEQ ID NOs in SG10201809895Y to the known sequences of evolocumab, it is not possible to definitively state if these are distinct molecules or simply further characterizations of related entities. However, the filing suggests an ongoing effort to innovate and protect its position in the PCSK9 inhibitor market.
What are the Potential Business Implications of SG10201809895Y?
The implications of Singapore patent application SG10201809895Y are significant for Amgen and its competitors in the hypercholesterolemia treatment market.
For Amgen:
- Strengthened IP Portfolio: If granted, SG10201809895Y would expand Amgen's intellectual property protection for PCSK9 inhibitors in Singapore, a key regional market. This can deter generic competition and provide a stronger basis for licensing or enforcement.
- Pipeline Diversification: The application suggests Amgen's continued investment in PCSK9 inhibitor research. These claims may cover next-generation antibodies with potentially improved therapeutic profiles, offering future product development opportunities.
- Market Exclusivity: Enhanced patent protection in a significant market like Singapore reinforces Amgen's market exclusivity for PCSK9 inhibitors, potentially prolonging the commercial lifecycle of its products.
- Strategic Defense: New patent filings can serve as a defensive measure against potential patent challenges by competitors or as a basis for cross-licensing negotiations.
For Competitors:
- Freedom to Operate (FTO) Challenges: Any company looking to develop or market PCSK9 inhibitors in Singapore would need to carefully assess their FTO concerning SG10201809895Y and Amgen's other PCSK9-related patents.
- Innovation Requirements: Competitors seeking to enter the market would need to develop antibodies that are demonstrably different from those claimed in this application and other Amgen patents, requiring significant R&D investment to achieve non-infringing innovations.
- Licensing Opportunities/Costs: If Amgen's patents are broadly protected, competitors may need to seek licenses, which could involve significant royalty payments or other commercial agreements.
- Market Entry Barriers: The robust patenting activity by Amgen and others in the PCSK9 space creates substantial barriers to entry for new players.
The economic impact hinges on the granted claims' scope and Amgen's ability to enforce them. Given Amgen's established position with Repatha, any new patent protection in this area directly supports its commercial strategy and competitive advantage. The specific SEQ ID NOs are critical for precise FTO analysis, but the general filing indicates continued proprietary interest and development in PCSK9 inhibition.
What is the Status of SG10201809895Y?
Singapore patent application SG10201809895Y, filed on November 2, 2018, is currently in the examination phase. As an application, it has not yet been granted as a patent. The applicant, Amgen Inc., is undergoing the process of patent examination with the Intellectual Property Office of Singapore (IPOS).
The typical stages of patent examination include:
- Filing and Formalities Examination: Initial checks on adherence to formal requirements.
- Publication: Applications are typically published after a certain period (usually 18 months from the filing date or priority date).
- Substantive Examination: IPOS examiners assess the application for patentability, including novelty, inventive step (non-obviousness), and industrial applicability, based on prior art.
- Office Actions: If objections are raised by the examiner, the applicant receives an Office Action and must respond by amending claims, providing arguments, or submitting further evidence.
- Grant or Refusal: Upon successful resolution of all objections, the patent is granted. If objections cannot be overcome, the application may be refused.
The applicant has likely submitted responses to any Office Actions issued by IPOS, engaging in dialogue to refine the claims and demonstrate patentability. The exact current status (e.g., pending further office actions, awaiting decision) can be tracked through IPOS's public database, if available. Until granted, the application does not confer exclusive rights, although it may provide provisional protection in some jurisdictions under specific circumstances. The final scope and enforceability of the invention will depend on the claims as they emerge from the examination process and are eventually granted.
Key Takeaways
- Singapore patent application SG10201809895Y, filed by Amgen Inc. on November 2, 2018, concerns human antibodies targeting PCSK9 for treating hypercholesterolemia.
- The application claims novel antibodies defined by specific amino acid sequences of their variable heavy and light chains, as well as compositions and methods of treatment.
- The patent landscape for PCSK9 inhibitors is highly competitive, marked by established drugs like Amgen's evolocumab and Regeneron/Sanofi's alirocumab, with significant prior art in place.
- SG10201809895Y aims to bolster Amgen's IP portfolio in Singapore, potentially covering next-generation antibodies or serving as a strategic defense for its PCSK9 inhibitor franchise.
- The application is currently under examination by the Intellectual Property Office of Singapore (IPOS), with its final scope and enforceability contingent on the granted claims.
Frequently Asked Questions
-
What specific SEQ ID NOs are critical in SG10201809895Y?
Claims 2 and 3 specify SEQ ID NO: 1 and SEQ ID NO: 2 for the VH and VL regions of one antibody, and SEQ ID NO: 3 and SEQ ID NO: 4 for another, providing precise structural definitions.
-
Has SG10201809895Y been granted as a patent in Singapore?
As of the current analysis, SG10201809895Y is an application and is undergoing examination; it has not yet been granted as a patent.
-
What is the primary therapeutic target of the antibodies claimed in SG10201809895Y?
The antibodies are designed to target and inhibit Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), a protein involved in regulating LDL cholesterol levels.
-
What are the existing approved PCSK9 inhibitors developed by Amgen?
Amgen's primary approved PCSK9 inhibitor is evolocumab, marketed as Repatha.
-
How does this application impact potential competitors in Singapore?
Competitors must conduct thorough freedom-to-operate analyses to avoid infringement, potentially requiring the development of non-infringing antibodies or seeking licenses if the patent is granted with broad claims.
Citations
[1] Amgen Inc. (2018, November 2). Human antibodies that bind to PCSK9 (Singapore Patent Application No. SG10201809895Y). Intellectual Property Office of Singapore.
